RE: stock pricePalnic,
I would do a little more research.
1. Do you really think that management spun off Atrium and took a wild as*s gues as to 60m is all they need for the next 3 years. Lets give them a little credit.
2. 19m burn/60m in cash. Assuming nothing changes for 3 years, they would need money in 2010. What you are forgeting is that AEZS has Milestone payments that will be coming in for their different drugs and compounds.
3. AEZS will be looking to establish a new partner for Perifosne, which will probably lead to more cash coming in. The stock will drift north as we get closer to phase 3 results at the end of the year.
Remember drug companies don't trade on fundamentals. This stock will be all trial result driven.